CMV seropositivity is a potential novel risk factor for severe COVID-19 in non-geriatric patients.

ABSTRACT:

Background

COVID-19 has so far affected more than 250 million individuals worldwide, causing more than 5 million deaths. Several risk factors for severe disease have been identified, most of which coincide with advanced age. In younger individuals, severe COVID-19 often occurs in the absence of obvious comorbidities. Guided by the finding of cytomegalovirus (CMV)-specific T cells with some cross-reactivity to SARS-CoV-2 in a COVID-19 intensive care unit (ICU) patient, we decided to investigate whether CMV seropositivity is associated with severe or critical COVID-19. Herpes simplex virus (HSV) serostatus was investigated as control.

Methods

National German COVID-19 bio-sample and data banks were used to retrospectively analyze the CMV and HSV serostatus of patients who exper

SUBMITTER: Weber S 

PROVIDER: S-EPMC9132318 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature